Why Healthcare Is Still the Least Digitalized Industry - Christoph Kausch (MTIP)
Innovation and Private Capital x auliumShow Notes
Healthcare remains one of the least digitalized industries — still largely operating in the "dinosaur phase" with paper records and fragmented systems. Yet the sector is expected to grow at over 20% annually for the next decade, creating massive opportunities for investors who understand both the technical and regulatory complexity of healthcare innovation.
Christoph Kausch, Managing Partner of MTIP, explains how healthcare technology investing differs fundamentally from traditional software. Long sales cycles, multiple stakeholders, and heavy regulation mean that explosive growth requires proven business models and real market traction first. Once adoption happens, however, the stickiness is unmatched — MTIP recently exited two companies, one growing more than 100% annually above €100 million in revenue, the other growing 80% on a profitable basis. The conversation covers how MTIP evaluates AI-enabled healthcare companies, the importance of cybersecurity in clinical settings, and why identifying multiple exit routes before investing is non-negotiable. Kausch also details the Oviva case study: a digital diabetes management company where MTIP led the Series B, helped build a cost-efficient platform, and saw enterprise value increase more than 15x.
Key discussion points:
🏥 Why healthcare tech requires sector specialization — understanding fragmented European systems, reimbursement models, and regulatory pathways is essential
🔒 Cybersecurity as infrastructure — MTIP's investment in Cynerio, sold to Axonius, reflects how hospitals are increasingly vulnerable to data breaches
📊 The profitability-first approach — MTIP invests in companies with proven revenue, not just promising technology
🌍 The US expansion challenge — scaling across Europe is hard; entering the US typically requires acquisition rather than organic growth
🎯 Exit preparation as daily practice — identifying strategic acquirers and PE buyers upfront, never relying on IPO timing
Watch the full episode: https://www.youtube.com/watch?v=iU5JBvTlViA
Subscribe to Aulium for more conversations on innovation and private capital.
About Christoph Kausch [Managing Partner of MTIP]:Managing Partner of MTIP, a Basel-based healthcare investment fund that shifted from medical devices in Fund I to focus exclusively on healthcare software from Fund II onward. Previously worked as an engineer at BMW before transitioning into healthcare investing. Guest lecturer at ETH Zurich and the University of St. Gallen, and recently joined as a panelist at LSI USA on the impact of GLP-1 drugs on medical devices.About Aulium:Aulium is a video show exploring Innovation and Private Capital, hosted by Thomas Viguier.Connect with us:➡ Aulium on LinkedIn: https://www.linkedin.com/company/aulium➡ Thomas Viguier: https://www.linkedin.com/in/tviguier/
More from Innovation and Private Capital x aulium
Africa receives roughly 1% of global venture capital, yet it has the youngest population on earth and digital adoption that is leapfrogging legacy infrastructure. So why does growth-stage capital remain so scarce?
Why are independent sponsors poised to take share from blind pool funds, and what does investing at the small end of the UK healthcare market really look like? Jim Weight of Weight Partners Capital argues that capital, not talent, is the binding constraint on the independent sponsor model.
Why do some of the hardest private equity deals, from messy carve-outs to opaque financials, produce the best returns? Zeina Bain of Sullivan Street Capital explains how she prices complexity that scares other buyers away.
Most venture investors chase hot sectors or optics-driven impact, yet a 40-year dataset suggests the real edge lies in backing companies that solve fundamental problems. Chris Corbishley of Benevolent Capital explains why outcomes matter more than optics.
Europe's energy gap is widening as electrification and data centers add demand faster than the grid can deliver, and Anna Teyssot of Exergon argues that innovation, not fossil fuels, has to close it.